If we earn tomorrow’s dividend and then get assigned at expiration on October 25, we will earn $1.65 per share on $52.95 per ...
The FDA on Thursday expanded the U.S.-approved indications for Bristol-Myers Squibb's (NYSE:BMY) blockbuster immunotherapy ...
The cuts follow an ongoing wave of staff reductions at big drug companies. Pharma giants have terminated thousands of ...
(Reuters) - Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene ...
A New York federal judge has dismissed a $6.4 billion lawsuit against Bristol-Myers Squibb Co., agreeing with counsel for ...
The Health Care Select Sector SPDR Fund ETF (NYSEARCA:XLV), tracking the healthcare companies under S&P 500, rose 6.27% in ...
Bristol-Myers Squibb Company ( NYSE:BMY ) stock is about to trade ex-dividend in two days. The ex-dividend date is ...
In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) cleared Opdivo (nivolumab) for use with platinum-based chemo to reduce the size ...
Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...
To mark the 10th anniversary of its Global Patient Week, Bristol Myers Squibb, a leading global biopharmaceutical company, ...